In Brief: Glaxo Wellcome plc
This article was originally published in The Tan Sheet
Executive Summary
Glaxo Wellcome plc: North American Operations Director Phillip Tracy, who oversaw Burroughs Wellcome's role in the Warner Wellcome OTC joint-venture prior to the Glaxo-Wellcome merger, has resigned, effective June 30. Tracy has headed Glaxo Wellcome's OTC business strategy since the merger. The OTC responsibilities move to James Cochrane as part of his oversight of business and commercial development. Two other executive directors also are resigning -- former Wellcome Group Research, Development and Medical Affairs Director David Barry and Group Marketing Director Keith Merrifield...